Deferred Revenue

12 Months Ended

Dec. 31, 2012

Deferred Revenue Disclosure [Abstract]

Deferred revenue consists of the following:



	As of December 31,
	2012		2011
Current portion:
Received or receivable from Sanofi (see Note 4a)	$	17,022	$	20,011
Received or receivable from Bayer HealthCare (see Note 4b)	9,212		7,907
Received for technology license agreement (see Note 5)	23,572		23,572
Other	1,025		150
	$	50,831	$	51,640
Long-term portion:
Received or receivable from Sanofi (see Note 4a)	$	76,520	$	86,017
Received or receivable from Bayer HealthCare (see Note 4b)	27,256		34,456
Received for technology license agreement (see Note 5)	104,566		128,137
	$	208,342	$	248,610

- Definition

The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References+ Details